125 results
8-K
EX-10.1
ADAP
Adaptimmune Therapeutics Plc
27 Feb 24
Adaptimmune Hires Chief Commercial Officer in Advance of Q3 2024 PDUFA Date for Afami-cel, a Late-stage Product in the Company’s Sarcoma Franchise
8:13am
subsidiaries or affiliates; (vi) Executive’s commission of fraud, misappropriation, embezzlement or theft; or (vii) Executive’s material breach
8-K
EX-10.3
adakp mtv25on3rf
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.4
ncbdr
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
8-K
EX-10.2
184wtl
1 Jun 23
Adaptimmune Announces Completion of Strategic Combination with TCR² Therapeutics Creating a Preeminent Solid Tumor Cell Therapy Company
4:09pm
424B3
q8n3 gkqh
20 Apr 23
Prospectus supplement
4:32pm
S-4/A
eosotr37n99lu9z
18 Apr 23
Registration of securities issued in business combination transactions (amended)
4:01pm
8-K
EX-10.1
0wtxoaa82
11 Apr 23
Adaptimmune and GSK Have Agreed Terms for Transfer of PRAME and NY-ESO Target Programs back to Adaptimmune
8:08am
S-4
u2y2vfqrenk4 31z
5 Apr 23
Registration of securities issued in business combination transactions
4:40pm